Diabetologia:2型糖尿病与听力损失发生率分析

2018-11-19 AlexYang MedSci原创

2型糖尿病已经被认为是一种听力损失的风险因子,可能的机制包括微血管疾病、听觉神经病变或者氧化胁迫。虽然有小部分研究调查2型糖尿病与听力损失之间的纵向性关系,但是跟大规模的研究是需要的。最近,有研究人员在2个前瞻性群体中调查了是否2型糖尿病与听力损失的发生率相关。研究人员进行的研究包括了139909名女性,并且调查了2型糖尿病与她们自我报道的听力损失发生之间的相关性,并从2年1次的调查问卷中确定了医

2型糖尿病已经被认为是一种听力损失的风险因子,可能的机制包括微血管疾病、听觉神经病变或者氧化胁迫。虽然有小部分研究调查2型糖尿病与听力损失之间的纵向性关系,但是跟大规模的研究是需要的。最近,有研究人员在2个前瞻性群体中调查了是否2型糖尿病与听力损失的发生率相关。

研究人员进行的研究包括了139909名女性,并且调查了2型糖尿病与她们自我报道的听力损失发生之间的相关性,并从2年1次的调查问卷中确定了医生诊断的糖尿病。研究发现,在他们的跟踪调查结果中,664个患有中度或者更加严重听力损失的案例具有2型糖尿病,并且10022个案例没有2型糖尿病。与那些没有2型糖尿病的女性患者相比,那些具有2型糖尿病的患者具有中度或者更严重听力损失发生的更高的风险(调整后集合多变量HR 1.16 [95% CI 1.07, 1.27])。另外,与那些不患有糖尿病参与者相比,那些具有2型糖尿病不少于8年的参与者有更高风险的中度或者更差听力损失(调整后集合多变量:HR 1.24 [95% CI 1.10, 1.40])。

最后,研究人员指出,在该大的纵向研究中,2型糖尿病与中度或者更差听力损失更高的风险具有相关性。进一步的是,更长时间的糖尿病与中度或者更差听力损失更高的风险相关。

原始出处:

Gupta S, Eavey RD, Wang M et al. Type 2 diabetes and the risk of incident hearing loss. Diabetologia. 6 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638865, encodeId=21d216388656e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 11 23:09:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826494, encodeId=cf6218264940c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 19 03:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760899, encodeId=40dd1e608998b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Feb 27 13:09:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306285, encodeId=269b1306285e3, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Nov 21 03:09:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042048, encodeId=078b104204822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Nov 19 15:09:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638865, encodeId=21d216388656e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 11 23:09:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826494, encodeId=cf6218264940c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 19 03:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760899, encodeId=40dd1e608998b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Feb 27 13:09:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306285, encodeId=269b1306285e3, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Nov 21 03:09:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042048, encodeId=078b104204822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Nov 19 15:09:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638865, encodeId=21d216388656e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 11 23:09:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826494, encodeId=cf6218264940c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 19 03:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760899, encodeId=40dd1e608998b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Feb 27 13:09:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306285, encodeId=269b1306285e3, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Nov 21 03:09:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042048, encodeId=078b104204822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Nov 19 15:09:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638865, encodeId=21d216388656e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 11 23:09:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826494, encodeId=cf6218264940c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 19 03:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760899, encodeId=40dd1e608998b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Feb 27 13:09:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306285, encodeId=269b1306285e3, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Nov 21 03:09:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042048, encodeId=078b104204822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Nov 19 15:09:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-11-21 ysjykql
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638865, encodeId=21d216388656e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 11 23:09:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826494, encodeId=cf6218264940c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Oct 19 03:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760899, encodeId=40dd1e608998b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Feb 27 13:09:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306285, encodeId=269b1306285e3, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Nov 21 03:09:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042048, encodeId=078b104204822, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Nov 19 15:09:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-11-19 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

BMJ:英国50万人研究称,女性受高血压、糖尿病和吸烟影响更大

BMJ发表一项基于UK Biobank近50万人的数据的研究表明,尽管男性心肌梗死发生率高于女性,与男性相比,高血压、糖尿病和吸烟与女性的心肌梗死的相关性更为密切。

J Clin Periodontol:刮治和根面平整、甲硝唑、阿莫西林治疗糖尿病及非糖尿病牙周炎的临床及微生物学研究

本文旨在评估患或不患糖尿病的牙周炎受试者接受刮治和根面平整(SRP),甲硝唑(MTZ)和阿莫西林(AMX)治疗后效果是否有差别。

J Clin Periodontol:牙周状况与2型糖尿病的关系

本实验旨在研究牙周病是否与2型糖尿病(T2DM)的发展有关。

JAHA:2型糖尿病患者肥胖与不良预后的相关性研究

近期研究显示糖尿病患者可能存在肥胖悖论现象。本研究的目的旨在评估2型糖尿病患者的不良预后事件与肥胖的关系。本研究纳入了ACCORD 临床研究中的有10年2型糖尿病史的患者。主要终点事件是全因死亡率,次要终点事件是心源性死亡、非致死性心梗和卒中。分析结果显示,三级肥胖患者(BMI≥40)的全因死亡率最高,二级肥胖其次,超重患者的风险最小。患者的BMI与腰围存在相关性(r=0.802),BMI与主要和

NEJM:糖尿病患者阿司匹林一级预防的效果如何?

2018年10月,《N Engl J Med》上发表的一项研究考察了糖尿病患者阿司匹林一级预防的效果。

带着爸妈远离糖尿病,你需要知道的五大事实和真相

在11月14日世界糖尿病日来临之际,搜狐健康整理了有关糖尿病的事实和数据,希望能帮助屏幕前的你和家人一起行动起来,远离糖尿病。一、全球4.25亿人罹患糖尿病,1/3患者在中国根据IDF去年公布的第八版的全球糖尿病地图,全球糖尿病成人患者(20岁—79岁)人数从2000年的1.51亿增加到了2017年的4.25亿。预计到2045年,糖尿病患者人数可达6.29亿。图1. 全球成人糖尿病患者(20岁